其中有氣喘診斷的處方共225,535次，非氣喘診斷的處方共5,248,532次。就單次處方僅使用一類抗氣喘藥物中以口服乙型支氣管擴張劑的使用用頻率最高，不論是在氣喘診斷組或非氣喘診斷組或是在不同年齡層都是最高(77.6%-52.6% Vs 84.8%-62.8%)。若是二類藥物合併使用則是以口服乙型支氣管擴張劑合併茶鹼或是乙型支氣管擴張劑合併口服類固醇是最常見的組合。至於在GINA準則中強調的控制型的吸入型類固醇則佔3.1~11.0%。綜合結論在有氣喘診斷及在非氣喘診斷下的醫師處方型態是類似的。自從1993年GINA(Global Initiative for Asthma)依病人的日、夜間症狀、發作頻率、尖峰吐氣流速等。將氣喘分成輕度間歇性、輕度持續性、中度持續性及重度持續性等四級。並依此分級而有不同的用藥。但這所有的用藥中，不外乎有幾大類，口服或吸入劑型的乙型支氣管擴張劑、口服或吸入劑型類固醇、茶鹼、白三烯受體拮抗劑等。本研究是採用健保局2002年1月份到3月份所有申報倉儲資料庫，共有5,474,067次處方箋。陳述性的研究此六大類抗氣喘藥物在有氣喘診斷及在非氣喘診斷下的醫師處方型態。
Guidelines from the Global Initiative for Asthma (GINA) mention several medications for the treatment of asthma. These medications include oral and inhaled beta-2 agonists, oral and inhaled corticosteroids, xanthines, leukotriene receptor antagonists, and their combinations. In addition to asthma, these drugs are commonly prescribed to treat other respiratory diseases, such as acute bronchitis, chronic cough, lower respiratory infection, or even bronchopneumonia. We analyzed differences in prescribing patterns between pediatric patients with and those without asthma, as coded in the claim records from the National Health Insurance Research Database. Oral beta-2 agonists were the most frequently monotherapy in both groups of patients (52.6-77.6% vs 62.8-84.8%). Oral beta-2 agonists combined with xanthines or oral corticosteroids combined with an oral beta-2 agonist were the most frequent combination therapies in both groups. Inhaled corticosteroids were used in 3.1-11.0% of patients with asthma; the rate varied by patient age. In conclusion, prescribing patterns were similar in pediatric patients with and those without asthma.
